Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.
Atrial fibrillation
Cardiac troponin
Fibrinolysis
GDF-15
NT-proBNP
Thrombin generation
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
03
04
2019
accepted:
26
06
2019
pubmed:
8
7
2019
medline:
29
12
2020
entrez:
8
7
2019
Statut:
ppublish
Résumé
We investigated whether growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-1), levels are associated with a prothrombotic state in atrial fibrillation (AF) as compared to N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI-hs). In 103 patients with AF assessed off anticoagulation (age: 71.0 [65.0-76.0] years; CHA
Identifiants
pubmed: 31280356
doi: 10.1007/s00392-019-01522-x
pii: 10.1007/s00392-019-01522-x
pmc: PMC7098929
doi:
Substances chimiques
Biomarkers
0
GDF15 protein, human
0
Growth Differentiation Factor 15
0
Peptide Fragments
0
Troponin I
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
426-434Subventions
Organisme : Jagiellonian University Medical College
ID : K/ZDS/007717
Références
Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, Hernandez-Romero D, Valdes M, Vicente V, Lip GY, Marin F (2017) Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep 7:41565. https://doi.org/10.1038/srep41565
doi: 10.1038/srep41565
pubmed: 28134282
pmcid: 5278507
Glowicki B, Matusik PT, Plens K, Undas A (2019) Prothrombotic state in atrial fibrillation patients with one additional risk factor of the CHA2DS2-VASc score (beyond sex). Can J Cardiol 35(5):634–643. https://doi.org/10.1016/j.cjca.2019.01.014
doi: 10.1016/j.cjca.2019.01.014
pubmed: 30955928
Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L, RE-LY and ARISTOTLE Investigators, Investigators A (2016) Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation 134(22):1697–1707. https://doi.org/10.1161/CIRCULATIONAHA.116.022802
doi: 10.1161/CIRCULATIONAHA.116.022802
pubmed: 27569438
Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L, ARISTOTLE and STABILITY Investigators (2016) The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 37(20):1582–1590. https://doi.org/10.1093/eurheartj/ehw054
doi: 10.1093/eurheartj/ehw054
pubmed: 26920728
pmcid: 4875560
Matusik PT, Matusik PS, Kornacewicz-Jach Z, Malecka B, Zabek A, Undas A (2017) Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. Int J Cardiol 243:244–250. https://doi.org/10.1016/j.ijcard.2017.05.060
doi: 10.1016/j.ijcard.2017.05.060
pubmed: 28571619
Matusik PT, Prior SM, Butenas S, Malecka B, Lelakowski J, Undas A (2018) Association of cardiac troponin I with prothrombotic alterations in atrial fibrillation. Kardiol Pol 76(7):1106–1109. https://doi.org/10.5603/KP.2018.0134
doi: 10.5603/KP.2018.0134
pubmed: 29984810
Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA (2019) Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 139(6):760–771. https://doi.org/10.1161/CIRCULATIONAHA.118.038312
doi: 10.1161/CIRCULATIONAHA.118.038312
pubmed: 30586727
pmcid: 6363338
Matusik PT (2019) Biomarkers and cardiovascular risk stratification. Eur Heart J 40(19):1483–1485. https://doi.org/10.1093/eurheartj/ehz265
doi: 10.1093/eurheartj/ehz265
pubmed: 31087049
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L, Investigators R-L Aristotle (2018) A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J 39(6):477–485. https://doi.org/10.1093/eurheartj/ehx584
doi: 10.1093/eurheartj/ehx584
pubmed: 29069359
Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, ARISTOTLE Investigators (2014) Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130(21):1847–1858. https://doi.org/10.1161/CIRCULATIONAHA.114.011204
doi: 10.1161/CIRCULATIONAHA.114.011204
pubmed: 25294786
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L (2017) Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Am Heart J 190:94–103. https://doi.org/10.1016/j.ahj.2017.06.001
doi: 10.1016/j.ahj.2017.06.001
pubmed: 28760218
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L, ARISTOTLE and RE-LY Investigators (2016) The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 387(10035):2302–2311. https://doi.org/10.1016/S0140-6736(16)00741-8
doi: 10.1016/S0140-6736(16)00741-8
pubmed: 27056738
Hu XF, Zhan R, Xu S, Wang J, Wu J, Liu X, Li Y, Chen L (2018) Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Clin Cardiol 41(1):34–38. https://doi.org/10.1002/clc.22844
doi: 10.1002/clc.22844
pubmed: 29363835
pmcid: 6489975
Hemker HC, Al Dieri R, De Smedt E, Beguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96(5):553–561
pubmed: 17080210
Hemker HC, Kremers R (2013) Data management in thrombin generation. Thromb Res 131(1):3–11. https://doi.org/10.1016/j.thromres.2012.10.011
doi: 10.1016/j.thromres.2012.10.011
pubmed: 23158401
Siudut J, Grela M, Wypasek E, Plens K, Undas A (2016) Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost 14(4):784–793. https://doi.org/10.1111/jth.13264
doi: 10.1111/jth.13264
pubmed: 26786481
Meus R, Son M, Sobczyk D, Undas A (2016) Prothrombotic state in patients with a left atrial appendage thrombus of unknown origin and cerebrovascular events. Stroke 47(7):1872–1878. https://doi.org/10.1161/STROKEAHA.116.012856
doi: 10.1161/STROKEAHA.116.012856
pubmed: 27301942
Bewick V, Cheek L, Ball J (2004) Statistics review 8: qualitative data—tests of association. Crit Care 8(1):46–53. https://doi.org/10.1186/cc2428
doi: 10.1186/cc2428
pubmed: 14975045
Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94(21):11514–11519. https://doi.org/10.1073/pnas.94.21.11514
doi: 10.1073/pnas.94.21.11514
pubmed: 9326641
Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM (2019) Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci 56(5):333–350. https://doi.org/10.1080/10408363.2019.1615034
doi: 10.1080/10408363.2019.1615034
pubmed: 31076013
Rossaint J, Vestweber D, Zarbock A (2013) GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost 11(2):335–344. https://doi.org/10.1111/jth.12100
doi: 10.1111/jth.12100
pubmed: 23231375
Eggers KM, Kempf T, Lind L, Sundstrom J, Wallentin L, Wollert KC, Siegbahn A (2012) Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 72(1):45–51. https://doi.org/10.3109/00365513.2011.626072
doi: 10.3109/00365513.2011.626072
pubmed: 22023041
Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA, Storey RF (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J 39(13):1078–1085. https://doi.org/10.1093/eurheartj/ehy013
doi: 10.1093/eurheartj/ehy013
pubmed: 29390064
pmcid: 6019045
Violi F, Pastori D, Pignatelli P, Loffredo L (2014) Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. Europace 16(8):1107–1116. https://doi.org/10.1093/europace/euu040
doi: 10.1093/europace/euu040
pubmed: 24706090
Pignatelli P, Menichelli D, Pastori D, Violi F (2018) Oxidative stress and cardiovascular disease: new insights. Kardiol Pol 76(4):713–722. https://doi.org/10.5603/KP.a2018.0071
doi: 10.5603/KP.a2018.0071
pubmed: 29537483
Drabik L, Wolkow P, Undas A (2017) Fibrin clot permeability as a predictor of stroke and bleeding in anticoagulated patients with atrial fibrillation. Stroke 48(10):2716–2722. https://doi.org/10.1161/STROKEAHA.117.018143
doi: 10.1161/STROKEAHA.117.018143
pubmed: 28904234
Janion-Sadowska A, Chrapek M, Konieczynska M, Undas A (2018) Altered fibrin clot properties predict stroke and bleedings in patients with atrial fibrillation on rivaroxaban. Stroke 50(1):185–188. https://doi.org/10.1161/STROKEAHA.118.023712
doi: 10.1161/STROKEAHA.118.023712
Thomas D, Christ T, Fabritz L, Goette A, Hammwohner M, Heijman J, Kockskamper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N (2019) German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. Clin Res Cardiol 108(6):577–599. https://doi.org/10.1007/s00392-018-1377-1
doi: 10.1007/s00392-018-1377-1
pubmed: 30306295
Litwinowicz R, Bartus M, Ceranowicz P, Kapelak B, Lakkireddy D, Bartus K (2018) Stroke risk reduction after left atrial appendage occlusion in elderly patients with atrial fibrillation: long-term results. Pol Arch Intern Med 128(5):327–329. https://doi.org/10.20452/pamw.4264
doi: 10.20452/pamw.4264
pubmed: 29768394
Feyz L, Theuns DA, Bhagwandien R, Strachinaru M, Kardys I, Van Mieghem NM, Daemen J (2019) Atrial fibrillation reduction by renal sympathetic denervation: 12 months’ results of the AFFORD study. Clin Res Cardiol 108(6):634–642. https://doi.org/10.1007/s00392-018-1391-3
doi: 10.1007/s00392-018-1391-3
pubmed: 30413869
Semmler V, von Krogh F, Haller B, Reents T, Bourier F, Telishevska M, Kottmaier M, Kornmayer M, Brooks S, Koch-Buttner K, Lennerz C, Brkic A, Grebmer C, Blazek P, Weigand S, Hessling G, Kolb C, Deisenhofer I (2019) The incidence, indications and predictors of acute pacemaker implantation after ablation of persistent atrial fibrillation. Clin Res Cardiol 108(6):651–659. https://doi.org/10.1007/s00392-018-1393-1
doi: 10.1007/s00392-018-1393-1
pubmed: 30460479
Maurer T, Rottner L, Makimoto H, Reissmann B, Heeger CH, Lemes C, Fink T, Riedl J, Santoro F, Wohlmuth P, Volkmer M, Mathew S, Metzner A, Ouyang F, Kuck KH, Sohns C (2018) The best of two worlds? Pulmonary vein isolation using a novel radiofrequency ablation catheter incorporating contact force sensing technology and 56-hole porous tip irrigation. Clin Res Cardiol 107(11):1003–1012. https://doi.org/10.1007/s00392-018-1270-y
doi: 10.1007/s00392-018-1270-y
pubmed: 29740700
Matusik PT, Tomala I, Piekarz J, Karkowski G, Kuniewicz M, Lelakowski J (2016) Thyroid goiter: implications for implantation of cardiovascular implantable electronic devices and cannulation of the superior vena cava confluence. Pol Arch Med Wewn 126(6):432–434. https://doi.org/10.20452/pamw.3459
doi: 10.20452/pamw.3459
pubmed: 27362396
de Jong MR, Hoogerwaard AF, Adiyaman A, Smit JJJ, Ramdat Misier AR, Heeg JE, van Hasselt B, Van Gelder IC, Crijns H, Lozano IF, Toquero Ramos JE, Javier Alzueta F, Ibanez B, Rubio JM, Arribas F, Porres Aracama JM, Brugada J, Mont L, Elvan A (2018) Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : the ASAF trial: ablation of sympathetic atrial fibrillation. Clin Res Cardiol 107(7):539–547. https://doi.org/10.1007/s00392-018-1214-6
doi: 10.1007/s00392-018-1214-6
pubmed: 29487995
Buist TJ, Adiyaman A, Smit JJJ, Ramdat Misier AR, Elvan A (2018) Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation. Clin Res Cardiol 107(6):498–506. https://doi.org/10.1007/s00392-018-1211-9
doi: 10.1007/s00392-018-1211-9
pubmed: 29411114
Sohns C, Metzner A, Chmelevsky M, Kuck KH (2018) A new algorithm to visualize the individual relationship between electrical rotors from non-invasive panoramic mapping and atrial fibrosis to guide ablation of persistent atrial fibrillation. Clin Res Cardiol 107(5):444–446. https://doi.org/10.1007/s00392-017-1196-9
doi: 10.1007/s00392-017-1196-9
pubmed: 29302740
Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA (2018) Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J 39(43):3867–3875. https://doi.org/10.1093/eurheartj/ehy421
doi: 10.1093/eurheartj/ehy421
pubmed: 30137304
Zabczyk M, Undas A (2017) Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med 127(12):873–881. https://doi.org/10.20452/pamw.4165
doi: 10.20452/pamw.4165
pubmed: 29225327
Undas A, Zabczyk M (2018) Antithrombotic medications and their impact on fibrin clot structure and function. J Physiol Pharmacol. https://doi.org/10.26402/jpp.2018.4.02
doi: 10.26402/jpp.2018.4.02
pubmed: 30415236